FDA OKs Injectable Semaglutide for Chronic Weight Management
The FDA approved Novo Nordisk's injectable semaglutide weight management (Wegovy) for adults with obesity or overweight. The GLP-1 receptor was approved for chronic weight management in adults with obesity (BMI of 30 or greater) or for adults with overweight (BMI 27 or greater) with at least one weight-related condition, such as high blood pressure, type 2 diabetes, or high cholesterol, used in conjunction with a reduced calorie diet and an exercise regimen. The once-weekly, injectable medication is approved at a dose of 2.4 mg for…